Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.
Level 5 - mechanism / opinion, no new human data
Narrative review describing observational associations and biological mechanisms without systematic review methods.
PubMed 18765113 · doi:10.1007/s11934-008-0035-y
What was done
This narrative review summarizes literature regarding the association between gonadotropin-releasing hormone (GnRH) agonist therapy in prostate cancer and the subsequent risks of developing diabetes and cardiovascular disease, alongside potential underlying biological mechanisms.
What was found
The abstract reports no numerical data, effect estimates, or statistical findings. It qualitatively notes that GnRH agonists are associated with adverse effects including vasomotor flushing, obesity, osteoporosis, and elevated risks of diabetes and cardiovascular disease.
Why it matters
Highlights non-oncologic, cardiometabolic morbidity associated with androgen deprivation therapy to prompt clinical awareness and cardiovascular risk assessment in prostate cancer survivors.
Limits
This is a narrative review presenting no systematic search methodology, meta-analysis, or primary human trial data in the abstract. Specific effect magnitudes, study populations, and quantitative risk metrics are not reported.
Cited by
- supports Cancer treatments, including cardiotoxic chemotherapy agents, increase patients' risks of developing secondary chronic conditions such as cardiovascular disease, osteoporosis, and diabetes.